

The Paradoxical Induction of Crohn's Disease Following Treatment of Psoriatic Arthritis With Etanercept

Mahtab Forouzandeh BS,^a Thomas Vazquez BS,^{a,b} Keyvan Nouri MD,^a Bahram Forouzandeh MD^c

^aUniversity of Miami Miller School of Medicine, Miami, FL

^bFlorida International University Wertheim College of Medicine, Miami, FL

^cUniversity of Kentucky College of Medicine, Lexington, KY

ABSTRACT

Introduction: While psoriasis, psoriatic arthritis, and Crohn's Disease (CD) all share a common central pathogenesis pathway and a wide overlap of treatment regime, discrepancies still exist and are highlighted by the variability in the effectiveness of certain immunomodulating agents. Etanercept, for example, has been shown to be ineffective in CD due to its inability to induce T-cell apoptosis in the intestinal mucosa.

Case: We describe the case of a 37-year-old man with a 20-year history of psoriatic arthritis. The patient presented with abdominal pain, watery diarrhea with mild hematochezia, and a reported 24-pound unintentional weight loss over the past five months. Of note, the patient began treatment with etanercept five months earlier after discontinuation of infliximab for his psoriatic arthritis symptoms. Colonoscopy with terminal ileum intubation revealed active colitis and intestinal biopsy results showed marked ulcerations and non-caseating granulomas, indicative of CD. Etanercept was subsequently discontinued and the patient was started on ustekinumab, leading to remission of both his psoriatic arthritis and new onset CD.

Discussion: Because the concurrent existence of psoriatic arthritis and IBD is becoming increasingly appreciated in recent literature, healthcare providers should have a high index of suspicion in patients with psoriasis and psoriatic arthritis presenting with unusual intestinal symptoms. Etanercept is intestinally inactive and should be used in caution in patients with psoriasis and psoriatic arthritis, as it may unmask underlying CD in this predisposed patient population. Dermatologists should also be aware of recent studies suggesting that etanercept directly contributes to the development of CD by altering the inflammatory cytokine milieu. Lastly, ustekinumab was successful in relieving our patient's cutaneous, joint, and gastrointestinal symptoms and may be considered an effective treatment option in patients suffering from both psoriasis and CD or the paradoxical induction of one disease entity secondary to treatment of the other.

J Drugs Dermatol. 2019;18(8):832-834.

INTRODUCTION

Psoriasis and psoriatic arthritis are observed at a frequency about eight times higher among patients with Crohn's disease (CD) than in the general population. Accordingly, a number of recent studies have revealed psoriasis and psoriatic arthritis as independent risk factors for the development of CD.¹ The link between these complex immune mediated inflammatory diseases is poorly understood; however, scientists postulate that it may be related to shared genetic abnormalities and common cytokine-driven inflammatory pathways (such as the interleukin (IL)-23 and Th17 pathways).²

While psoriasis, psoriatic arthritis, and CD all share a common central pathogenesis pathway and a wide overlap of treatment regime, discrepancies still exist. These differences are highlighted by variabilities in the effectiveness of certain immunomodulating agents, such as etanercept.

Etanercept is a recombinant dimer of human tumor necrosis factor (TNF) receptor proteins bound to human IgG1 and is an effective treatment for psoriasis, among other autoimmune diseases.³ However, etanercept has been shown to be ineffective in CD, due to its inability to induce T-cell apoptosis in the intestinal mucosa.⁴ Ustekinumab, on the other hand, has been shown to be particularly effective for the management of both CD and psoriasis due to its targeting of IL-12 and IL-23.^{2,5}

CASE REPORT

We report a case of a 37-year-old obese male with a 20-year history of psoriatic arthritis with cutaneous involvement who was treated with etanercept (50 mg weekly) after discontinuation of infliximab, due to insurance requirements. The patient presented with a 2-month history of moderate to severe left upper quadrant pain radiating to the periumbilical area and a 4-month

history of watery diarrhea with mild hematochezia. He also reported an unintentional 24-pound weight loss over the 5 months following the initiation of etanercept. His vitals were normal and past medical, surgical, and social history were unremarkable. The patient had no family history of any autoimmune conditions to his knowledge.

Physical examination was pertinent for diffuse abdominal tenderness to palpation, erythematous annular scaly plaques present on both his elbows and knees, and mild joint deformities. The CBC with differential and iron panel were both unremarkable. Pertinent labs include a normal liver panel and an elevated C-reactive protein of 25 (0-10 mg/dL). Stool PCR and culture were both negative. Colonoscopy with terminal ileum intubation showed active colitis with nodular and focally ulcerative mucosa with pseudomembranes present predominantly in the left, right, and sigmoidal colon segments (Figure 1). Pathology results showed moderate active colitis with marked ulcerations and non-caseating granulomas indicative of CD (Figure 2). Of note, IgA and IgG antibody testing for *saccharomyces cerevisiae*, a useful adjunct test for differentiating CD from ulcerative colitis, was highly suggestive of CD in this patient.

Etanercept was subsequently discontinued and the patient was started on ustekinumab with an IV induction dose of 520 mg administered over one hour. He was prescribed 90 mg subcutaneous maintenance dosing every 8 weeks. The patient experienced remission of both his PA and his new onset CD four weeks following ustekinumab therapy.

DISCUSSION

The paradoxical induction of psoriasis has been well established in patients who were treated for inflammatory bowel disease (IBD) with TNF inhibitors.⁶ Recent studies have proposed that the development of CD should be suspected in patients with psoriatic arthritis receiving etanercept who develop gastrointestinal symptoms.⁷ Although the mechanism underlying this event remains unknown, it is postulated that, in predisposed patients, treatment with etanercept may alter the inflammatory cytokine environment, promoting the development of CD. As a result, etanercept may not only induce, but may accelerate the development of CD in predisposed individuals.⁸ Thus, it is possible that etanercept induced new-onset CD in our already at-risk patient. This phenomenon has recently been reported in psoriasis treated with adalimumab, inciting the development of ulcerative colitis.⁹ This report by Kolios et al supports the theory of biologics-induced inflammatory bowel disease (IBD) because their patient's "paradoxical ulcerative colitis" was improved not by switching to an IBD-effective treatment, but by merely ceasing treatment with adalimumab.⁹

Given the increasing co-occurrence of psoriatic arthritis and CD, the unmasking of underlying disease is another possible

FIGURE 1. Multiple distinct colonic ulcers with loss of vascular pattern and friable mucosa.





FIGURE 2. Non-caseating granulomas indicative of Crohn's disease.



theory in our patient. Etanercept is known to be an ineffective treatment for inflammatory bowel disease as it is not intestinally active. With this in mind, it is possible that our patient's underlying CD was unmasked by switching him from an intestinally active TNF- α inhibitor, infliximab, to an intestinally inactive TNF- α inhibitor, etanercept. This theory may be supported by Ruemmele et al'

s case of CD which developed during the treatment of juvenile idiopathic arthritis with etanercept.¹⁰ The child in this case was experiencing mild gastrointestinal symptoms that dramatically increased after initiation of etanercept, suggesting that etanercept either allowed or enhanced the development of CD.

This report is particularly salient for dermatologists as most reported cases of TNF-inhibitor induced pathologies have resulted from the treatment of non-cutaneous conditions and therefore may have escaped the attention of dermatologists. Our case encourages physicians to consider the risk of adverse gastrointestinal effects when prescribing etanercept for psoriatic arthritis.⁹ Future research should focus on identifying the underlying mechanism for the paradoxical development of CD in patients treated with etanercept and explore whether etanercept induces or merely permits the development of CD. Because the concurrent existence of psoriatic arthritis and IBD is becoming increasingly appreciated in recent literature, healthcare providers should have a high index of suspicion in patients with psoriasis and psoriatic arthritis presenting with unusual intestinal symptoms. Lastly, ustekinumab was successful in relieving

our patient's cutaneous, arthritic, and gastrointestinal symptoms and may be considered an effective treatment option in patients suffering from both psoriasis and CD or the paradoxical induction of one disease entity secondary to treatment of the other.⁹

DISCLOSURES

The authors have no conflicts of interest to declare.

REFERENCES

1. Egeberg A, Mallbris L, Warren RB, et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. *Br J Dermatol*. 2016;175(3):487-492.
2. Baumgart DC, Sandborn WJ. Crohn's disease. *Lancet*. 2012;380(9853):1590-1605.
3. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. *Arthritis Rheum*. 2003;48(4):1093-1101.
4. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. *Gastroenterology*. 2001;121(5):1088-1094.
5. Deepak P, Sandborn WJ. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. *Gastroenterol Clin North Am*. 2017;46(3):603-626.
6. Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management. *Nat Rev Rheumatol*. 2014;10(10):612-627.
7. Ahmad K, Rogers S. Development of Crohn disease in a patient on etanercept for psoriasis. *Br J Dermatol*. 2007;157(2):396-396.
8. Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. *J Dermatolog Treat*. 2018;29(1):13-18.
9. Kolios AGA, Biedermann L, Weber A, et al. Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab. *Br J Dermatol*. 2018;178(2):551-555.
10. Ruemmele FM, Prieur AM, Talbotec C, Goulet O, Schmitz J. Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis. *J Pediatr Gastroenterol Nutr*. 2004;39(2):203-206.
11. Oh J, Arkfeld DG, Horwitz DA. Development of Crohn's disease in a patient taking etanercept. *J Rheumatol*. 2005;32(4):752-753.

AUTHOR CORRESPONDENCE

Mahtab Forouzandeh BS

E-mail:..... M.forouzandeh@umiami.edu